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Abstract
Tetherin/BST-2/CD317 is a recently identified antiviral protein that blocks the release of nascent retrovirus, and other virus,
particles from infected cells. An HIV-1 accessory protein, Vpu, acts as an antagonist of tetherin. Here, we show that positive
selection is evident in primate tetherin sequences and that HIV-1 Vpu appears to have specifically adapted to antagonize
variants of tetherin found in humans and chimpanzees. Tetherin variants found in rhesus macaques (rh), African green
monkeys (agm) and mice were able to inhibit HIV-1 particle release, but were resistant to antagonism by HIV-1 Vpu. Notably,
reciprocal exchange of transmembrane domains between human and monkey tetherins conferred sensitivity and resistance
to Vpu, identifying this protein domain as a critical determinant of Vpu function. Indeed, differences between hu-tetherin
and rh-tetherin at several positions in the transmembrane domain affected sensitivity to antagonism by Vpu. Two
alterations in the hu-tetherin transmembrane domain, that correspond to differences found in rh- and agm-tetherin
proteins, were sufficient to render hu-tetherin completely resistant to HIV-1 Vpu. Interestingly, transmembrane and
cytoplasmic domain sequences in primate tetherins exhibit variation at numerous codons that is likely the result of positive
selection, and some of these changes coincide with determinants of HIV-1 Vpu sensitivity. Overall, these data indicate that
tetherin could impose a barrier to viral zoonosis as a consequence of positive selection that has been driven by ancient viral
antagonists, and that the HIV-1 Vpu protein has specialized to target the transmembrane domains found in human/
chimpanzee tetherin proteins.
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Introduction
Eukaryotic cells can constitutively or inducibly express a variety
of molecules that inhibit the replication of viruses. Among these
antiviral defenses are components of the type-I interferon (IFN) -
induced innate immune system [1,2]. In turn, viruses have evolved
to express proteins that either limit IFN-induced gene expression
or directly antagonize the function of antiviral proteins.
We and others recently identified an IFN-induced antiviral
protein, termed tetherin, that functions by a novel mechanism.
Specifically, tetherin blocks the release of nascent virions from HIV-
1 infected cells [3–5]. Tetherin is an integral membrane protein
with a unique topology. In particular, it encodes a transmembrane
anchor towards its N-terminus, as well as a putative glycopho-
sphatidyl-inositol lipid anchor at its C-terminus [6]. These two
membrane anchors are linked by an extracellular domain that is
predictedtoform a coiled-coil. Ectopic expressionoftetherinincells
that do not ordinarily express it results in the formation of protease-
sensitive tethers that causes retention of retrovirus particles on the
surface of infected cells, from where they can be internalized
[4,5,7,8]. This pronounced ability to retain and internalize HIV-1
particles is present constitutively in cells that normally express
tetherin, but is suppressed when tetherin is depleted. Tetherin
colocalizes with Gag and appears to act by inducing adherence of
virion and cell membranes. Thus, virions that are retained by
tetherin are fully formed and mature, and have lipid bilayers that
are discontinuous with cell membranes [4,7].
Notably, an HIV-1 accessory transmembrane protein, Vpu, acts
as a viral antagonist of tetherin [4,5]. Indeed tetherin dramatically
inhibits the release of Vpu-defective HIV-1 virions, but has only
modest effects on wild-type Vpu-expressing HIV-1. Moreover,
Vpu colocalizes with tetherin and prevents the localization of
tetherin to nascent virions, perhaps through its ability to reduce
the amount of tetherin at the cell surface [4,5]. Thus, the existence
of tetherin explains the previously observed requirement for Vpu
during HIV-1 particle release from certain cells, particularly those
that have been exposed to type-I IFN [3,7,9–12].
The wide expression of tetherin upon exposure of cells to IFN-
alpha [4,13] and the wide range of retroviruses and filoviruses that
are inhibited by tetherin [8] suggests that it might be a general
component of an innate immune defense against many enveloped
viruses. As such, tetherin could provide an impetus for the
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Kaposi’s sarcoma herpesvirus (KSHV) also encodes a likely
antagonist of tetherin, since expression of the KSHV K5 protein
decreases the steady state level of tetherin protein [14].
Additionally, certain retroviral envelope proteins, in particular
the HIV-2 Env, have Vpu-like activity [15,16]. Thus, it seems
likely that tetherin antagonists other than Vpu exist.
Here, we show that tetherin proteins from different species
exhibit marked differences in sensitivity to antagonism by HIV-1
Vpu. Specifically, tetherin proteins from two old world monkey
species as well as from mouse, are effective inhibitors of HIV-1
particle release, but are resistant to Vpu. Moreover, we show that
the transmembrane domain of tetherin contains determinants of
sensitivity to Vpu, and that two mutations in the human tetherin
sequence are sufficient to generate a protein that is entirely
resistant to antagonism by Vpu. Interestingly, tetherin sequences
that are predicted to be accessible to cytoplasmic or integral
membrane antagonists, such as HIV-1 Vpu, exhibit evidence of
positive selection at numerous codons, including some that we
demonstrate determine the effectiveness of Vpu antagonism. Thus,
past selective pressures imposed on tetherin by viral antagonists
likely provides a barrier to the establishment of zoonotic infections
by modern primate lentiviruses, and potentially enveloped viruses
from other species, whose spread depends on antagonism of
tetherin function.
Results
Resistance of nonhuman tetherin proteins to antagonism
by HIV-1 Vpu
Inspection of sequence databases revealed the presence of
putative tetherin proteins in various mammalian species. For
functional analyses, we amplified tetherin sequences from cDNAs
derived from rhesus macaque (rh), African green monkey (agm),
chimpanzee (cpz) and mouse (mo). Coexpression of hu-tetherin,
cpz-tetherin, rh-tetherin, agm-tetherin, mo-tetherin, with HIV-1
(delVpu) caused a marked decease in the yield of viral particles, as
measured using infectivity or western blot assays (Fig. 1 A,B,C).
The magnitude of the reduction in virus yield varied somewhat,
depending which tetherin protein was coexpressed. In each case,
inhibition of virion release by tetherin did not lead to a dramatic
accumulation of cell associated viral proteins. This finding suggest
that the virions that are retained by tetherin, are destroyed at rate
that exceeds, or is not greatly different, to their synthesis. This
would likely be through endocytosis, followed by lysosomal
degradation. Moreover, it may simply be the case that only a
fraction of the viral protein that is synthesized by infected cells is
actually released as particles. Thus the amount of viral protein that
is observed in cell lysates would be determined by its intrinsic
turnover rate, rather than particle release versus retention.
The differences in potency that were observed among the
various tetherin proteins were only partly explained by variation in
the levels at which each tetherin was expressed (Fig. 1, Fig. S1A), A
finding which suggests that natural variation in potency may exist
among mammalian tetherin proteins, and that hu-tetherin is
particularly potent. However, a caveat to be attached to this
conclusion is that transiently expressed tetherin exisits as a variety
of species, presumably reflecting heterogeneous glycosylation. At
present it is not clear whether all of the various tetherin species are
active, and it is possible that the amount of active tetherin is not
uniformly represented in analyses of total tetherin protein levels.
Nonetheless, each tetherin protein was clearly capable of reducing
infectious HIV-1(delVpu) yield, by 20-fold or more. Strikingly,
however, and in contrast to hu-tetherin, the rh-, agm- and mo-
tetherin proteins were equally efficient in reducing HIV-1(WT)
and HIV-1(delVpu) virion yield (Fig. 1A,B,C). Conversely, as with
hu-tetherin, HIV-1(WT) was substantially resistant to inhibition by
cpz-tetherin, while the release of HIV-1(delVpu) particles was
strongly inhbited (Fig. 1 D, E). Thus, the non-hominid tetherin
proteins were apparently insensitive to antagonism by HIV-1 Vpu.
while both hu-tetherin and cpz-tetherin were Vpu-sensitive.
Tetherin transmembrane sequences can transfer
resistance or sensitivity to Vpu
Earlier work indicated that expression of an intact transmem-
brane (TM) segment of HIV-1 Vpu was most important, and
perhaps sufficient, to enhance HIV-1 particle release [17]. This
finding, combined with the notion that only the N-terminal
portion of tetherin should be physically accessible to Vpu,
suggested the possibility that Vpu might target the transmembrane
domain of tetherin. Thus, we generated chimeric proteins, termed
hu(agmTM) and hu(rhTM), in which the transmembrane domain
of hu-tetherin was replaced with corresponding sequences from rh-
or agm-tetherin. These chimeric proteins differed in the
magnitude with which they inhibited HIV-1 virion release,
concordant with differences in expression level (Fig. S1B), but
both were entirely resistant to antagonism by Vpu (Fig. 2A, C).
Indeed, the hu-tetherin protein containing the agm TM domain
inhibited both HIV-1(delVpu) and HIV-1(WT) particle release
with similar or greater potency with which the intact hu-tetherin
protein selectively blocked HIV-1(delVpu) release (Fig 2A, C).
In a reciprocal experiment, rh-tetherin and agm-tetherin
proteins encoding a hu-tetherin transmembrane domain were
generated. The rh(huTM) protein was expressed at a slightly
higher level and was a more effective inhibitor of HIV-1 particle
release than was the agm(huTM) protein (Fig. 2B,C, Fig. S1B).
However, both proteins selectively inhibited HIV-1(delVpu)
particle release, indicating that they were sensitive to antagonism
by HIV-1 Vpu. Thus, the exchange of the TM domain between
tetherin proteins from different species transferred sensitivity and
resistance to antagonism by HIV-1 Vpu.
Author Summary
Tetherin is a cell surface protein that acts as an antiviral
defense. It functions by tethering newly assembled HIV-1
particles to the surface of the infected cell, such that the
viral particle is unable to depart and disseminate to other,
uninfected cells. HIV-1 possesses an antagonist of tetherin,
termed Vpu, that abolishes tetherin function. We found
that HIV-1 is an effective antagonist of human and
chimpanzee variants of tetherin but is unable to antago-
nize tetherins from two monkey species. Additionally, we
found that sequence differences in a portion of the protein
that is embedded in cell membranes determined whether
or not it could be antagonized by Vpu. Since the Vpu
protein is alsi a membrane embedded protein, this result
suggests that Vpu and tetherin interact within cell
membranes. We also show that tetherin has been evolving
rapidly, and has likely been placed under selective pressure
to change sequence. Notably, portions of tetherin that
appear to have been placed under selective pressure
coincide with positions that influence Vpu antagonism.
Therefore, the evolutionary history of primates determines
the effectiveness of HIV-1 Vpu in modern species. Thus,
tetherin could impose a barrier to cross species transmis-
sion of retroviruses.
Positive Selection in Tetherin and Vpu Activity
PLoS Pathogens | www.plospathogens.org 2 February 2009 | Volume 5 | Issue 2 | e1000300Figure 1. Effect of nonhuman tetherins on HIV-1 particle release and antagonism by Vpu. A, B) Western blot analysis (anti HIV-1 capsid,
p24) of cell and virion lysates following transfection of cells with WT and Vpu deleted (delVpu) proviral plasmids, alone (none) or in combination with
50 ng of the indicated human (hu) rhesus monkey (rh) African green monkey (agm) tetherin-HA expression plasmids (A) or 50 ng of hu- or mouse
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Inspection of tetherin TM domain protein sequences revealed
several differences between the monkey and human proteins,
distributed along the length of the TM domain (Fig. 3A). To
determine which of these were responsible for the Vpu resistance
of the monkey tetherin proteins to antagonism by Vpu, we
generated mutant forms of hu-tetherin, each bearing an individual
change in the TM domain that is found at the corresponding
position in rh-tetherin. (The exceptions to this scheme were the
L23V,L24I mutant in which two contiguous amino acids were
changed to their rh-tetherin counterparts and the delGI change,
where a two amino acid deletion that is present in the rh-tetherin
sequence was introduced). This panel of mutant tetherin proteins
varied in the potency with which they reduced HIV-1(delVpu)
virion yield, and in their ability to be antagonized by Vpu
(Fig. 3B,C). Variation in the potency of antiviral activity among
Figure 2. Tetherin TM domains are determinants of sensitivity/resistance to HIV-1 Vpu. A, B) Western blot analysis (anti HIV-1 capsid, p24)
of cell and virion lysates following transfection of cells with WT and Vpu deleted (delVpu) proviral plasmids, either alone (none) or in combination
with 50 ng of plasmids expressing chimeric human tetherin-HA proteins encoding monkey-derived TM domains (A), or monkey tetherin-HA proteins
encoding a human tetherin TM domain (B). C) Infectious virion yield, measured as in Fig. 1, following transfection of cells with WT and delVpu proviral
plasmids, with varying amounts of the indicated tetherin-HA expression plasmids.
doi:10.1371/journal.ppat.1000300.g002
(mo) HA-tetherin expression plasmids (B). Numbers to the left of the blots indicate the positions of molecular weight markers. C) Infectious virion
yield, measured using HeLa-TZM indicator cells and given in relative light units (RLU), following transfection of cells with WT and Vpu deleted
(delVpu) proviral plasmids, in combination with varying amounts of the indicated tetherin-HA or HA-tetherin expression plasmids. D) Western blot
analysis (anti HIV-1 capsid, p24) of cell and virion lysates following transfection of cells with WT and Vpu deleted (delVpu) proviral plasmids in
combination with 100 ng of untagged human (hu) or chimpanzee (cpz) tetherin expression plasmids. Numbers to the left of the blots indicate the
positions of molecular weight markers. E) Infectious virion yield, measured using HeLa-TZM indicator cells and given in relative light units (RLU),
following transfection of cells with WT and Vpu deleted (delVpu) proviral plasmids, in combination with 100 ng of hu-tetherin or cpz-tetherin
expression plasmids.
doi:10.1371/journal.ppat.1000300.g001
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(Fig. S1C). Notably, none of the individual hu-tetherin mutants
recapitulated the phenotype of the rh-tetherin or hu(rhTM)-
tetherin proteins that appeared completely resistant to Vpu
antagonism. Rather, several of the individual mutants appeared
partly resistant to antagonism by Vpu, in that Vpu was not able
enhance virion release as effectively in their presence as it did in
the presence of unmanipulated hu-tetherin (Fig. 3B,C). Because
these analyses were slightly confounded by the variation in the
potency and expression of the individual tetherin mutants, we
measured infectious HIV-1(WT) and HIV-1(delVpu) virion yield
in the presence of varying levels of the mutant tetherin proteins
(Fig. 4). Overall, these analyses identified a single amino acid
difference (P40L) as contributing substantially to the Vpu
sensitivity of hu-tetherin and the Vpu-resistance of rh-tetherin.
Other changes in the hu-tetherin TM had more modest effects, or
no effect on Vpu sensitivity, when present in isolation, or
substantially affected tetherin potency (Fig. 3, Fig. 4).
Because our initial analysis revealed that no single change in the
TM domain of hu-tetherin could abolish sensitivity to Vpu, we
next tested whether mutations that individually had minor or
partial effects on Vpu antagonism could exert more dramatic
effects when present in combination. In particular, several
mutations were combined with the most obvious difference
between human and monkey tetherin TM domains, namely the
delGI change. Notably, the delGI,T45I double mutant strongly
Figure 3. Effects of individual TM domain mutations on tetherin potency and Vpu antagonism. A) Differences between hu- and rh-
tetherin TM domains. The human (left) and rhesus (right) sequences are depicted, from the cytoplasmic face (lower) to the extracellular face (upper)
of the plasma membrane; an integrin beta3 transmembrane segment was used to model the position of the differences. B) Western blot analysis (anti
HIV-1 capsid, p24) of cell and virion lysates following transfection of cells with WT and Vpu deleted (delVpu) proviral plasmids, alone (none) or in
combination with 50 ng of the indicated unmanipulated or mutant hu-tetherin-HA expression plasmids. C) Infectious virion yield, measured as in
Fig. 1, following transfection of cells with WT and Vpu deleted (delVpu) proviral plasmids, in combination with 50 ng of the indicated mutant hu-
tetherin-HA expression plasmids. Numbers above each pair of bars indicate the fold difference in virion yield when WT and delVpu viruses are
compared.
doi:10.1371/journal.ppat.1000300.g003
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antagonism by Vpu (Fig. 5A,B). Additionally, the I33V,I36L
combination mutation which would be predicted to target
proximal residues on the face of a TM alpha helix (Fig. 3A)
appeared to confer at least partial resistance to antagonism by
Vpu. However, this double mutation generated a tetherin protein
with only modest activity. Nonetheless, when combined with a
mutation at a third proximal residue (generating V30G,I33-
V,I36L) this combined mutation conferred partial resistance to
Vpu antagonism, in the context of a protein with potent antiviral
activity (Fig. 5A, B). Moreover a hu-tetherin bearing combined
delGI,I33V,I36V mutations was almost completely resistant to
antagonism by Vpu, and exhibited substantial antiviral activity
(Fig. 5A, B). Finally, combining the delGI mutation with
subsitiutions at contiguous residues that corresponded to rh-
tetherin residues (delGI, L23V,L24I) resulted in a protein with
only weak inhibitory activity, whereas combining the delGI
mutation with contiguous L23A,L24V mutations (corresponding
to agm-tetherin residues) generated a protein that was potent and
partly Vpu resistant (Fig. 5A, B). Notably, the differences in
activity and Vpu sensitivity among the various combination-
mutant tetherin proteins was not explained by differences in
expression level (Fig. S1D).
To determine whether mutations that conferred resistance to
antagonism by Vpu in virion release assays also conferred
resistance to the previously described phenomenon of Vpu-
induced downregulation of hu-tetherin from the cell surface [5],
we generated cell lines stably expressing either wild type hu-
Figure 4. Effects of individual TM domain mutations on tetherin potency and Vpu antagonism. Each chart shows infectious virion yield,
measured as in Fig. 1, following transfection of cells with WT and Vpu deleted (delVpu) proviral plasmids, in combination with varying amounts of the
indicated mutant hu-tetherin-HA expression plasmids.
doi:10.1371/journal.ppat.1000300.g004
Positive Selection in Tetherin and Vpu Activity
PLoS Pathogens | www.plospathogens.org 6 February 2009 | Volume 5 | Issue 2 | e1000300Positive Selection in Tetherin and Vpu Activity
PLoS Pathogens | www.plospathogens.org 7 February 2009 | Volume 5 | Issue 2 | e1000300tetherin-HA protein or the Vpu-resistant delGI/T45I hu-tetherin
mutant (Fig. 6). Upon infection with HIV-1 (WT), hu-tetherin was
efficiently depleted from the surface of the vast majority of infected
cells (Fig. 6A, B). Conversely, infection with HIV-1 (delVpu)
resulted in little or no hu-tetherin downregulation from the surface
of infected cells. Strikingly, and unlike the WT hu-tetherin protein,
Figure 6. A tetherin mutant that is resistant to antagonism by Vpu is also resistant to surface downregulation by Vpu. A) 293T cells
stably expressing either WT or mutant (delGI/T45I) hu-tetherin were infected with VSV-G pseudotyped HIV-1(WT) or HIV-1(delVpu) variants that
carried Cerulean-FP (CFP, green), as indicated. Cells were fixed but not permeabilized in order to confine tetherin-HA staining to surface expressed
protein (red). B) Cells were scored visually for the presence (tetherin +) or absence (tetherin 2) of intense tetherin-HA staining on the cell’s surface
(see examples in panel (A)). Greater than 95% of the uninfected WT or delGI/T45I hu-tetherin-HA expressing cells exhibited intense surface tetherin-
HA expression. At least seventy individual CFP-positive infected cells were evaluated for surface tetherin-HA expression each experimental condition.
doi:10.1371/journal.ppat.1000300.g006
Figure 5. Effects of combined TM domain mutations on tetherin potency and Vpu antagonism. A) Western blot analysis (anti HIV-1
capsid, p24) of cell and virion lysates following transfection of cells with WT and Vpu deleted (delVpu) proviral plasmids, alone (none) or in
combination with 50 ng of the indicated unmanipulated or mutant hu-tetherin-HA expression plasmids. B) Infectious virion yield, measured as in
Fig. 1, following transfection of cells with WT and delVpu proviral plasmids, with varying amounts of the indicated mutant tetherin-HA expression
plasmids.
doi:10.1371/journal.ppat.1000300.g005
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surface upon infection with HIV-1 (WT) (Fig. 6A, B) and, thus,
was resistant to surface downregulation by Vpu.
Overall, these experiments revealed that no single difference
between the hu-tetherin and rh-tetherin proteins accounted for
their respective sensitivity and resistance to antagonism by HIV-1
Vpu. Rather, they indicated that the particular combination of
residues in the tetherin TM domain can affect antiviral potency,
and that multiple differences between human and monkey
proteins, including the delGI indel, and the I33V, I36L, P40L
and T45I differences, influence the differential sensitivity of
tetherins to antagonism by Vpu.
Intraspecies polymorphism and evidence of positive
selection in tetherin.
Inspection of a larger collection of mammalian tetherin
sequences amplified from various old world primates, or retrieved
from sequence databases, revealed some striking features. Firstly,
among the nonprimate mammalian tetherin sequences, the N-
terminal cytoplasmic domain was hypervariable, both in length
and sequence (data not shown). Because of these properties, it
proved impossible to unambiguously align non-primate and
primate tetherin sequences in order to perform tests for positive
selection. Therefore, we confined further analyses to primate
tetherin sequences, which could be aligned unambiguously
throughout the entire length of the coding sequence. Even within
primates there was considerable sequence divergence between
species, ranging from 0.5% to 40.0% at the nucleotide level.
Sampling within three old world monkey species (rhesus
macaques, pig-tailed macaques and sooty mangabeys) also
revealed the presence of significant polymorphism within species
(Fig. S2 and data not shown); it remains to be seen whether
nonsynonymous polymorphism extends to the tetherin locus of
other primate lineages. Positive selection was tested using the
REL(HyPhy) [18] and CODEML (PAML) [19] methods and
these analyses revealed that codons exhibiting high dN/dS ratios,
and therefore likely to have been subjected to positive selection,
were enriched in the N-terminal cytoplasmic and TM domains in
primate tetherins (Fig. 7). Tetherin evolution in primates was also
evaluated under several standard models of sequence evolution as
implemented in the CODEML program. These comprise three
nested pairs of models (M0 and M3; M1a and M2a; M7 and M8)
in which the second model of each pair is derived from the first by
allowing sites to evolve under positive selection. Nested models
were compared using the likelihood ratio test, and in each case
allowing individual sites to evolve under positive selection (M3,
M2a, M8) gave a significantly better fit to the primate sequence
data than the corresponding model without positive selection (M0,
M1a and M7, respectively) (Table 1). The M3, M2a and M8
models identified a largely overlapping set of sites in the tetherin
coding sequence with dN/dS.1, consistent with an evolutionary
history characterized by frequent episodes of positive selection.
Notably, some codons that exhibited a high probability of having
evolved under positive selection coincided with residues that
determined the effectiveness of Vpu antagonism (Fig. 7). However,
there were numerous additional codons, particularly in the
tetherin cytoplasmic domain, that also exhibited high dN/dS
ratios, suggesting that antagonists other than Vpu have also
imposed selective pressure on primate tetherin sequences.
Figure 7. Positive selection in primate tetherin sequences. A diagram representing the various domains of the tetherin protein is shown,
below plots of the dN/dS ratio (upper plot) and the Bayes factor for dN.dS (lower plot) at each codon in an alignment of primate tetherin coding
sequences. Sequences from human, chimpanzee, gorilla, gibbon, African green monkey, pigtail macaque (2 variants), rhesus macaque (4 variants),
long tail macaque (2 variants), sooty mangabey (2 variants), and marmoset were used in the analysis (see Fig. S2 for the codon alignment). Also
indicated are residues in hu-tetherin that contribute to HIV-1 Vpu sensitivity.
doi:10.1371/journal.ppat.1000300.g007
Table 1. Models of evolution applied to primate tetherin
sequences.
Comparison 2(Ln1-Ln0)* d.f. x
2
M0, M3 40.8 4 p,0.00001
M1a, M2a 14.2 2 p,0.0008
M7, M8 13.8 2 P,0.001
*The likelihood ratio test (LRT) was used to compare two nested models of
sequence evolution, in which one model is a more complex version of the
other. The LRT is used to justify the additional assumptions that are
incorporated in the more complex model (or to reject the more complex
model in favor of the simpler model) by asking whether the additional
assumptions result in a statistically significant improvement in fit to the data.
For the three comparisons indicated, the second model only differs from the
first in permitting some form of positive selection to act on individual sites. The
LRT is conducted by calculating twice the difference in maximum likelihood
scores for the two models under comparison and then finding the chi-square
critical value. For a recent discussion of these models and their evaluation
using the LRT, see reference [24].
d.f. - degrees of freedom.
doi:10.1371/journal.ppat.1000300.t001
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Previously, we reported that Vpu could reverse the inhibitory
effect of IFN-alpha on HIV-1 particle release from human cells,
but that Vpu failed to reverse such IFN-alpha induced inhibition
in African green monkey cells [3]. The subsequent discovery that
tetherin is an IFN-induced inhibitor that is antagonized by Vpu
[4,5] leads to the prediction that agm-tetherin should be resistant
to Vpu. Here we show that agm-tetherin, as well as rh-tetherin and
mo-tetherin are indeed resistant to antagonism by Vpu, in contrast
to tetherin variants found in species (human and chimpanzee) that
are permissive hosts for HIV-1. Moreover, these studies identify
the TM domain of hu-tetherin as a major determinant of the
effectiveness of Vpu antagonism. That the TM domain of tetherin
harbors critical determinants of Vpu sensitivity is concordant with
previous observations indicating that the TM domain of Vpu is
critical for its virus release activity [17]. Thus, these observations
suggest a model in which Vpu and tetherin interact via their TM
domains. Such an interaction could be direct, but further work will
be required to resolve whether this is indeed the case, and precisely
how Vpu tetherin antagonism and/or downregulation from the
cell surface is achieved is not known. In this regard, the recent
report suggests that the host cell protein CAML is important for
Vpu activity [20], but how tetherin, Vpu and CAML interact in a
functional sense is unclear at present.
Importantly, no single change in the hu-tetherin TM domain
abolished Vpu sensitivity, which is consistent with a model in
which Vpu, or a bridging factor, makes multiple contacts with the
TM domain of tetherin. Indeed, the hu-tetherin mutant,
delGI,T45I, that had the most striking phenotype, in that it
retained full activity but was completely resistant to antagonism by
Vpu, harbored mutations at positions close to the opposing ends of
the TM domain. Additionally, a different combination of
mutations (delGI, I33V, I36L) also conferred complete Vpu
resistance, again consistent with the notion that multiple contacts
with the tetherin TM domain are made during its antagonism by
Vpu. Concordant with these findings, the chimpanzee and human
tetherin proteins were both sensitive to HIV-1 Vpu, and differed
from each other at only a single position in their TM domains.
Thus, it is likely only minor, if any, adaptation in the SIVCPZ Vpu
protein that is immediately ancestral to the HIV-1 Vpu proteins
would have been required in order for it to target human tetherin.
Primate tetherin TM domain sequences, that should only be
accessible to integral membrane antagonists, exhibit clear evidence
of positive selection at several codons, including some that
determine the effectiveness of Vpu antagonism. Thus, it is likely
that antagonists encoded by pathogenic viruses have driven the
selection of the tetherin variants that exist in modern primates.
Such antagonists could include Vpu itself, since several primate
lentiviruses encode Vpu proteins (http://www.hiv.lanl.gov/).
However, other viral antagonists, including the KSHV K5 protein
[14], or homolgues of it, are also reasonable candidates for factors
that have imposed selective pressure on tetherin sequences. In
addition to the TM, several sites with the highest dN/dS ratios
mapped to the N-terminal cytoplasmic domain. Such sites may
define an accessible target exploited by other virally encoded
inhibitors of tetherin. It is noteworthy in this regard that many
primate lentiviruses do not encode a Vpu like protein, and may
have evolved alternative strategies targeting this or other regions of
the protein. Additionally, tetherin sequences might also have
evolved to better target specific types of viral particles in some host
species, as a consequence of varying viral challenges. Such
evolution might also include adaptations in domains of tetherin
that, for example, modify its trafficking within cells (likely
including the cytoplasmic and TM domains). Overall, there are
several potential sources of evolutionary pressure that could give
rise to positive selection and diversification of tetherin genes. We
note that the sequence of the TM domain of tetherin is obviously
constrained by the need to retain the biochemical characteristics of
a TM domain, which might mitigate against the detection of
positive selection in this protein domain.
HIV-1 is well adapted to replicate in human cells, but fails to
replicate in many nonhuman primate cells. This is in large part
because it is unable to evade or antagonize the species-specific
variants of antiviral genes, such as TRIM5 and APOBEC3, which
show evidence of positive selection that is assumed to have resulted
from past retroviral epidemics [21–23]. Tetherin represents a third
example of an antiviral gene in monkeys that exhibits activity
against intact HIV-1 as a consequence of positive selection in the
primate lineage. Thus an array of antiviral molecules limit the
replication of primate lentiviruses in non-natural host cells,
creating barriers to zoonosis, and revealing potential opportunities
to mobilize intrinsic antiretroviral defenses by therapeutic
inhibition of the activity of their viral antagonists.
Materials and Methods
Plasmid construction
A hu-tetherin cDNA, cloned into pCR3.1 vector, and its N-
terminally HA tagged counterpart have been described previously
[4]. An internally HA-tagged tetherin expression construct,
pCR3.1/hu-tetherin-HA was derived from this by inserting an
NheI restriction site at nucleotide position 463 of the tetherin gene.
Thereafter, complimentary oligonucleotides encoding an HA
epitope tag were inserted into the NheI site. Similarly, the tetherin
coding sequence from rhesus macaque, African green monkey
chimpanzee and mouse was amplified using cDNA generated from
IFN-alpha treated 221, COS-7, chimpanzee fibroblasts, and
NIH3T3 cells respectively. For the monkey tetherins, the HA
epitope was inserted at a position orthologous to nucleotide 463 as
described above, while a N-terminally tagged murine tetherin
construct was used. Thereafter, overlap-extension PCR approach-
es were used to exchange TM domain segments between human
and monkey proteins, or to introduce point mutations into the hu-
tetherin sequence.
Cells and transfection
293T cells were maintained in DMEM media supplemented
with 10% fetal calf serum and gentamycin, as were HeLa-TZM
cells which express CD4 and CCR5 and contain a lacZ reporter
gene under the control of an HIV-1 LTR. To measure tetherin
and Vpu activity, 293T cells were seeded in a 24 well plate at a
concentration of 1.5610
5 cells/well and transfected the following
day using polyethylenimine (PolySciences) with 500 ng of an
unmanipulated HIV-1 proviral plasmid NL4-3(WT) or a Vpu-
defective counterpart NL4-3(delVpu). Additionally, 50 ng of a
tetherin expression plasmid and 50 ng pCR3.1/cherry fluorescent
protein (to monitor transfection efficiency) were included in the
transfection. In experiments where the level of tetherin was varied,
the tetherin expression plasmids were serially diluted from 200 ng
to 12.5 ng per transfection and pCR3.1 was used as a DNA filler.
Stable WT and mutant hu-tetherin-HA expressing 293T-derived
cell lines were generated by retroviral transduction, as previously
described [8].
Virion yield assays
Transfected 293T cells were place in fresh medium at 20 hrs
post transfection and virion containing cell supernatants were
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Infectious virus release was determined by inoculating, in
triplicate, sub-confluent monolayers of HeLa-TZM cells seeded
in 48 well plates at 2.5610
4 cells/well with 50 ml of serially diluted
supernatants. At 48 hrs post infection, ß-galactosidase activity was
determined using GalactoStar reagent as per the manufacturer’s
instructions. The remainder of the virion containing supernatant
(450 ml) was layered onto 800 ml of 20% sucrose in PBS and
centrifuged at 20,000 g for 90 minutes at 4uC and virion yield
determined by western blot assays
Western Blot assays
Pelleted virions and the corresponding cell lysates were
resuspended in SDS-PAGE loading buffer and separated on
NuPAGE Novex 4–12% Bis-Tris Mini Gels (Invitrogen). Proteins
were blotted onto nitrocellulose membranes. Thereafter, HIV-1
Gag or capsid proteins, as well as tagged tetherin proteins were
revealed using anti-capsid and anti-HA antibodies and chemilu-
minescent detection reagents, as described previously.
Microscopy
293T cells stably expressing either WT or mutant (delGI/T45I)
tetherin-HA were plated on poly-D-lysine coated dishes (Mattek).
The following day the cells we infected with VSV-G pseudotyped
HIV-1(WT) or HIV-1(delVpu) variants that carried Cerulean-FP
(CFP) embedded in the stalk region of the matrix domain of Gag.
The virus dose was chosen so that approximately 40% of the cells
were infected. At 48 h after infection, cells were fixed but not
permeabilized in order to confine tetherin-HA staining to surface
expressed protein. Fixed cells were sequentially incubated with an
anti-HA monoclonal antibody (Covance) followed by an anti
mouse IgG Alexafluor 594 conjugate. The cells were imaged using
a Deltavision microscopy suite and infected cells (identified by the
presence of CFP fluorescence) were scored for the presence of
intense tetherin-HA staining on the cell surface.
Tetherin sequence retrieval and analysis
The aforementioned human, chimpanzee, rhesus monkey,
African green monkey and mouse sequences were included in an
analysis for positive selection. In addition, tetherin genes were
amplified from lymphocyte RNA from several rhesus macaques
(n=8) pigtail macaques (n=1), crab eating macaques (n=6) and
sooty mangabeys (n=6). These were cloned using a kit TOPO-TA
kit (Invitrogen) and the sequences of multiple clones determined.
Representative alleles were included in the analysis described
below. Additional tetherin sequences from gorilla, gibbon, and
marmoset were retrieved from the raw data archives of ongoing
genome sequencing projects by TraceBLAST (http://www.ncbi.
nlm.nih.gov/BLAST/Blast.cgi), using each of the hu-tetherin
coding exons as a separate query. Sequences were aligned using
Macvector, and adjusted manually. Codon-based nucleotide
alignments were used in conjunction with phylogenetic trees
generated using the DNAPARS program (PHYLIP) as input for
the random effects likelihood (REL) program (HyPhy) to detect
positive selection. Input files for analysis using CODEML in the
PAML suite (version 3.14) were generated by first aligning amino-
acid sequences using the CLUSTAL-W algorithm, converting the
alignment back to nucleotides, and adjusting manually where
necessary using MEGALIGN (DNASTAR, Madison, WI). Tree
files were generated by Neighbor-Joining, and sites with dN/dS.1
were identified using the resulting tree or a tree constrained to
accept the known major branches of primate evolution as input,
with similar results. The F3X4 model of codon frequencies was
used for all analyses in CODEML. Paired, nested models of
sequence evolution implemented in CODEML (M0, M3; M1,
M2; M7, M8) were also compared using the likelihood ratio test.
Evaluation with the chi-square test assumed either 4 degrees of
freedom (M0, M3) or 2 degrees of freedom (M1,M2; M7, M8).
Supporting Information
Figure S1 Western blot analysis of tetherin-HA and HA-tetherin
expression. In each case cells were transfected with 50 ng of a
tetherin expression plasmid. (A) Intact primate and mouse
tetherin-HA or HA-tetherin proteins, as indicated, see Fig. 1. (B)
Chimeric tetherin-HA proteins, in which the TM domans were
exchanged, see Fig. 2. (C) Individual mutant hu-tetherin-HA
proteins, see Fig. 3, 4. (D) Combination mutant hu-tetherin-HA
proteins, see Fig. 5.
Found at: doi:10.1371/journal.ppat.1000300.s001 (1.19 MB PDF)
Figure S2 Alignment of tetherin protein sequences, from human
(hu), chimpanzee (Cpz), gorilla (Gor), gibbon (Gib), African Green
monkey (Agm), macaques (nemenstrina, Mac(n)1,2), (mulatta,
Mac(m)db,1,2,3), fasicularis, Mac(f)1,2), sooty mangabeys (Sm1,2)
and Marmoset (Mar). Alignments were derived using Macvector,
with adjustments by hand. Corresponding codon-matched nucle-
otide alignments were used in analyses of positive selection (see
Fig. 7).
Found at: doi:10.1371/journal.ppat.1000300.s002 (0.17 MB PDF)
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